Molecule profile · Module 4
Tesamorelin — evidence and research limits
This label describes the research context of this profile, not a product-by-product approval determination. It does not mean every use of the molecule lacks approval. Read the existing evidence details and regulatory context for the specific preparation, indication and jurisdiction; no new approval is inferred.
MOLECULE PROFILE
- Evidence summary
- Investigational — profile context
- Falutz and colleagues studied adults with HIV-associated lipodystrophy. The U.S. product indication concerns excess abdominal fat in that population, not general weight management or longevity. EGRIFTA WR and SV have formulation-specific administration instructions; evidence for one product or schedule cannot be transferred to an unrelated preparation. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The source discusses EGRIFTA WR/SV in the specific context of excess abdominal fat in adults with HIV and lipodystrophy. Those presentations and their labeling must not be treated as interchangeable or expanded to general body recomposition. The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
Tesamorelin acts in the growth hormone-releasing hormone pathway. Its main clinical evidence in the course concerns adults with HIV-associated lipodystrophy and excess abdominal fat. A reduction in a specific visceral-fat compartment is not the same endpoint as general weight reduction, athletic performance, or reversal of aging.
What the evidence supports
Falutz and colleagues studied adults with HIV-associated lipodystrophy. The U.S. product indication concerns excess abdominal fat in that population, not general weight management or longevity. EGRIFTA WR and SV have formulation-specific administration instructions; evidence for one product or schedule cannot be transferred to an unrelated preparation.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The source discusses EGRIFTA WR/SV in the specific context of excess abdominal fat in adults with HIV and lipodystrophy. Those presentations and their labeling must not be treated as interchangeable or expanded to general body recomposition. The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Label context: active malignancy, hypersensitivity, and pregnancy are among the contraindications; review hypothalamic-pituitary axis, glucose, IGF-1, and fluid retention according to the product. Do not reconstruct a community regimen from the label. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Sport and anti-doping status
The WADA 2026 Prohibited List names tesamorelin among growth hormone-releasing hormone analogues in section S2.2.4, prohibited at all times (in and out of competition). A product approval for HIV-associated lipodystrophy does not change that classification. This is an anti-doping classification, separate from clinical evidence, product quality and regulatory approval. Medical supervision, a prescription or an approved indication does not by itself permit use in sport; any exemption for a documented medical condition is a separate decision by the competent anti-doping organization. The List is revised each year, so check the List in force on the relevant date.
Continue learning
Explore Module 4 in PEPTIDE Academy for the full evidence discussion.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- FDA. EGRIFTA WR, Prescribing Information, March 2025. Tesamorelin reference by presentation.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. DOI: 10.1056/NEJMoa072375. PMID: 18057338.DOI 10.1056/NEJMoa072375 · PMID 18057338
- EGRIFTA WR (tesamorelin). U.S. prescribing information, version 1 (March 2025). DailyMed, National Library of Medicine.
- World Anti-Doping Agency. International Standard: Prohibited List 2026 (in effect from 1 January 2026). Checked 19 October 2026.
Related resources
Molecule profile · Module 4
CJC-1295 without DAC
Products described as CJC-1295 without DAC are discussed in relation to growth hormone-releasing hormone signaling. The name needs special scrutiny: a modified growth hormone-releasing factor sold without DAC cannot be treated as the same intervention as the long-acting CJC-1295 investigated in the cited human study. Molecular characterization precedes any comparison of exposure or hormone response.
Molecule profile · Module 4
Ipamorelin
Ipamorelin is investigated as an agonist of the ghrelin receptor, a target involved in growth hormone release and gastrointestinal physiology. The cited postoperative-ileus study addresses a specific surgical setting. A receptor mechanism or a measured hormone response does not establish improved strength, sleep, body composition, or the performance of a combination product.
Molecule profile · Module 4
Sermorelin
Sermorelin is discussed in the context of growth hormone-releasing hormone receptor signaling and pituitary responsiveness. Stimulation of the axis is a physiological response, not a direct measure of better sleep, greater strength, or longer life. Results from a different GHRH analogue or from growth hormone itself cannot establish the same effects for sermorelin.